Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Genetics, BioIQ Partner on NGS-Based SARS-CoV-2 Variant Detection

NEW YORK – Fulgent Genetics and BioIQ announced Tuesday a partnership to identify variants of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing.

BioIQ, an Atlanta-based diagnostic testing software company, will offer Fulgent's coronavirus genome sequencing assay on its software platform to its employer, government, and health plan customers to inform testing regimens, clinical treatment protocols, and vaccination strategies.

Financial and other terms of the deal were not disclosed.

"With new COVID-19 variants emerging around the globe, there is growing concern that higher infectivity in some strains may result in faster spread of the virus," BioIQ Founder, President, and COO Justin Bellante said in a statement. "This tool will be an important addition in the diagnostic armamentarium against COVID-19 by enabling BioIQ and its customers to more rapidly identify and quarantine individuals in cases where more infectious variants are present."

Temple City, California-based Fulgent began developing its coronavirus sequencing assay in March 2020.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.